- https://doi.org/10.1089/vim.2024.0076
Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study.
Translate Article 
Take Notes Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first identified in Wuhan, China, in December 2019, has led to global efforts in vaccination to mitigate rising morbidity and mortality, with vaccines proving crucial in controlling the pandemic. This study evaluated the humoral responses to the inactivated virus vaccine Sinopharm or Koxing Kerlafor, the protein subunit vaccine ZF001, and the adenoviral vector vaccine Convidecia after 18 months of inactivated virus vaccination by heterologous and homologous booster vaccination in patients with previous SARS-CoV-2 infection and healthy individuals. We discovered that patients who had recovered from the infection and then received a third vaccine dose (booster) exhibited durable immunity. Furthermore, the heterologous booster vaccine induced higher neutralizing antibody responses compared with the homologous booster. These findings offer valuable insights into the efficacy of different COVID-19 vaccine strategies following booster immunization.
- Peer Review Report
- 10.7554/elife.83694.sa1
- Feb 9, 2023
Decision letter: Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
- Peer Review Report
- 10.7554/elife.83694.sa0
- Feb 9, 2023
Editor's evaluation: Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
- Research Article
21 - 10.1053/j.gastro.2021.09.009
- Sep 8, 2021
- Gastroenterology
Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?
- Research Article
- 18
- 10.1016/j.ccell.2022.01.010
- Jan 25, 2022
- Cancer cell
Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor Tcell immunotherapy recipients.
- Discussion
- 13
- 10.1016/j.kint.2021.08.020
- Sep 7, 2021
- Kidney International
Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis
- Front Matter
- 10.1016/j.ekir.2021.05.036
- Jun 9, 2021
- Kidney International Reports
Humoral Response to SARS-CoV-2 in Hemodialysis Patients
- Research Article
- 187
- 10.1016/j.jhep.2021.01.032
- Feb 6, 2021
- Journal of hepatology
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
- Front Matter
- 5
- 10.1053/j.ajkd.2021.10.003
- Dec 23, 2021
- American Journal of Kidney Diseases
SARS-CoV-2 Vaccine in Dialysis Patients: Time for a Boost?
- Research Article
- 10.1016/j.ptdy.2021.07.022
- Aug 1, 2021
- Pharmacy Today
Immunization Update 2021
- Discussion
- 97
- 10.1016/j.kint.2021.03.002
- Mar 24, 2021
- Kidney International
Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy
- Discussion
- 5
- 10.1002/ajh.26406
- Nov 23, 2021
- American Journal of Hematology
Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.
- Discussion
- 21
- 10.1016/j.kint.2021.11.024
- Dec 8, 2021
- Kidney International
Observations on improving COVID-19 vaccination responses in kidney transplant recipients: heterologous vaccination and immunosuppression modulation
- Discussion
- 176
- 10.1016/j.kint.2021.04.005
- Apr 20, 2021
- Kidney International
Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine
- Discussion
- 62
- 10.1016/j.kint.2021.08.017
- Aug 30, 2021
- Kidney International
A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response
- Discussion
- 52
- 10.1016/j.kint.2021.04.008
- Apr 20, 2021
- Kidney International
Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving hemodialysis: a call to arms
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
